|
DISCOVERY LABS IN, (DSCO) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Discovery Laboratories, Inc., a biopharmaceutical company, develops Surfactant Replacement Therapies for respiratory diseases. The company offers Surfaxin, a protein B-based agent, for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories provides Surfaxin, which is in Phase 2 clinical trials, for bronchopulmonary dysplasia in premature infants, neonatal respiratory disorders in premature infants, and prophylactic/early treatment of meconium aspiration syndrome in full-term infants. It also offers its products for the treatment of acute respiratory distress syndrome in adults in the intensive care unit, as well as a Phase 1b trial of its lung surfactant delivered as an inhaled aerosol for patients who suffer from asthma. In addition, the company evaluating the development of aerosolized formulations of its SRT to prevent or treat acute lung injury, COPD, rhinitis, sinusitis, sleep apnea, and otitis media. It has a strategic alliance with Quintiles Transnational Corp., PharmaBio Development, Inc., and Laboratorios del Dr. Esteve S.A. The company is headquartered in Warrington, Pennsylvania.
|
DISCOVERY LABS IN Related |
|
Discovery Laboratories, Inc. Focusing on diseases of the lung, with its initial emphasis on the treatment of neonatal indications.
|
|
Welcome to Discovery Labs Discovery Labs' Aerosolized KL-4 Surfactant Selected for Evaluation in Phase 2a ... Discovery Labs and FDA to Meet on June 18, 2008 to Clarify Limited Items in ...
|
|
Surfaxin New Drug Application Discovery Labs anticipates submitting a Complete Response in September 2008 and ... In addition, Discovery Labs is contemporaneously conducting a related ...
|
|
